Advertisement

Topics

STAT Plus: Merck scraps plans to sell a biosimilar version of Lantus as the insulin market gets crowded

13:43 EDT 12 Oct 2018 | STAT

In an unexpected move, Merck (MRK) scrapped plans to market a biosimilar version of the widely used Lantus insulin only a year after winning tentative U.S. regularly approval. The decision…

Original Article: STAT Plus: Merck scraps plans to sell a biosimilar version of Lantus as the insulin market gets crowded

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Merck scraps plans to sell a biosimilar version of Lantus as the insulin market gets crowded"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...